Fig. 1From: Cost-effectiveness of bevacizumab plus paclitaxel versus paclitaxel for the first-line treatment of HER2-negative metastatic breast cancer in specialist oncology centers in FranceSchematic diagram of Markov model utilized in the cost-effectiveness analysisBack to article page